Close Menu
    Latest Category
    • Finance
    • Tech
    • EU Law
    • Energy
    • About
    • Contact
    EUbusiness.com | EU news, business and politicsEUbusiness.com | EU news, business and politics
    Login
    • EU News
    • Focus
    • Guides
    • Press
    • Jobs
    • Events
    • Directory
    EUbusiness.com | EU news, business and politicsEUbusiness.com | EU news, business and politics
    Home » Cocaine seizures in Europe hit all-time high: EU drugs report

    Cocaine seizures in Europe hit all-time high: EU drugs report

    npsnps6 June 2019
    — Filed under: EU News Headline2 Health Living & Working in EU Social
    Share
    Facebook Twitter LinkedIn Pinterest Email
    Cocaine seizures in Europe hit all-time high: EU drugs report

    Drugs cocaine

    (BRUSSELS) – Seizures of cocaine are at record levels in Europe, with signs of an increase in the drug’s availability, according to the European Drug Report released by the EU’s drugs agency on Thursday.

    According to the ‘European Drug Report 2019: Trends and Developments’, released by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), over 104,000 cocaine seizures were reported in the EU in 2017, compared with 98,000 in 2016.

    In its annual overview, the agency also explores challenges associated with heroin and new synthetic opioids, the latest developments in the cannabis market, Europe’s growing role in synthetic drug production and the use of digital technologies for health benefits in the drugs field.

    “Drugs remain a constantly evolving, multi-faceted threat to our societies, affecting the life of millions of citizens around the world,” said Home Affairs Commissioner Dimitris Avramopoulos. He called for a more coordinated approach that tackles both supply and demand, and said EU efforts – such as new rules to ban psychoactive substances and enhanced cooperation with international partners – were bearing fruit. But he added that “we also need to look at the role of digitalisation in the drug market. We have no time to spare. We need to be coordinated at the national, European and international levels.”

    The EMCDDA report highlights the continuing high availability of most illicit substances. The latest data show that in Europe (EU-28, Turkey and Norway), over 1 million seizures of illicit drugs are reported annually. Around 96 million adults in the EU (15–64 years) have tried an illicit drug in their lifetime and an estimated 1.2 million people receive treatment each year for illicit drug use (EU-28). In 2018, 55 new psychoactive substances (NPS) were detected in the EU for the first time, bringing the total number monitored by the agency to 730.

    EMCDDA Director Alexis Goosdeel warned against “an evolving market where synthetic drugs and drug production within Europe are growing in importance. This can be seen in problems associated with the use of highly potent synthetic opioids, in new production techniques for MDMA and amphetamines, and in recent developments in the processing of morphine into heroin inside Europe’s borders.”

    Heroin is still the most common illicit opioid on the drug market in Europe and is a major contributor to drug-related health and social costs. The quantity of heroin seized in the EU increased by over a tonne in 2017 to 5.4 tonnes, with an additional 17.4 tonnes seized by Turkey (some of which would have been destined for the EU market).

    The report says that the current opioid epidemic in the United States and Canada is largely driven by the use of synthetic opioids, particularly fentanyl and its derivatives. While these substances currently represent only a small share of the drug market in Europe, they are a growing concern, with use linked to poisonings and deaths.

    As for cannabis, this remains the most widely used illicit drug in Europe, as evident in data on prevalence, seizures and new treatment demands. Some 17.5 million young Europeans (15–34 years) are estimated to have used cannabis in the last year (EU-28 — 2017 estimate).

    European Drug Report 2019: Trends and Developments (EMCDDA)

    Add A Comment
    Leave A Reply Cancel Reply

    You must be logged in to post a comment.

    nps
    • Website

    Related Content

    EMBL logo

    Strategy Officer, European Molecular Biology Laboratory, EMBL

    Fitto - Mînzatu - Photo © European Union 2026

    EUR 34.6 bn cohesion funds reallocated to EU’s strategic priorities

    Health research - Photo by National Cancer Institute on Unsplash

    Brussels awards EUR 617m to doctoral programmes

    Trade port cargo - Image by Pexels from Pixabay

    EU trade in goods with Australia in 2025

    Online teaching call centre - Photo by MART PRODUCTION on Pexels

    Why Europe’s AI Translation Boom Still Needs a Human in the Loop in 2026

    Business finance - Image by Credit Commerce from Pixabay

    UK Lenders Unite with £11 Billion Boost to Support British Businesses

    LATEST EU NEWS
    Fitto - Mînzatu - Photo © European Union 2026

    EUR 34.6 bn cohesion funds reallocated to EU’s strategic priorities

    25 March 2026
    Health research - Photo by National Cancer Institute on Unsplash

    Brussels awards EUR 617m to doctoral programmes

    25 March 2026
    Trade port cargo - Image by Pexels from Pixabay

    EU trade in goods with Australia in 2025

    25 March 2026
    Sefcovic - von der Leyen - Albanese - Photo © European Union 2026

    EU and Australia conclude talks on trade agreement

    24 March 2026
    Putin - Image by svklimkin from Pixabay

    Brussels renews support for exiled and relocated journalists in the EU

    23 March 2026

    Subscribe to EUbusiness Week

    Get the latest EU news

    CONTACT INFO

    • EUbusiness, 117 High Street, Chesham Buckinghamshire, HP5 1DE, United Kingdom
    • +44(0)20 8058 8232
    • service@eubusiness.com

    INFORMATION

    • About Us
    • Advertising
    • Contact Info

    Services

    • Cookie Policy
    • Terms
    • Disclaimer

    SOCIAL MEDIA

    Facebook
    eubusiness.com © EUbusiness Ltd 2026

    Type above and press Enter to search. Press Esc to cancel.

    Manage Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    • Manage options
    • Manage services
    • Manage {vendor_count} vendors
    • Read more about these purposes
    View preferences
    • {title}
    • {title}
    • {title}

    Sign In or Register

    Welcome Back!

    Login to your account below.

    Lost password?